BMS-767778 

BMS-767778 is an orally active and selective DPP4 inhibitor with K_i values of 0.94 nM, 4.9, 3.2 nM for DPP4, DPP8 and DPP9 respectively. BMS-767778 exhibits >3,000-fold selectivity over the related enzymes DPP8 and DPP9. BMS-767778 inhibits CYP-3A4 with IC₅₀ of 5.2 μM. BMS-767778 significantly reduces blood glucose levels in high fat fed (HFD) ob/ob mice with safety profile. BMS-767778 can be used for diabetes mellitus research^[1].

BMS-767778 (compound 2s) exhibits good passive membrane permeability, with PAMPA effective permeability (P_e) values of 19.7, 129.7, and 330 × 10^-6 cm/s at pH 5.5, 6.5, and 7.4, respectively^[1].
BMS-767778 displays an efflux ratio (basolateral-to-apical / apical-to-basolateral permeability) of greater than 5 in Caco-2 cell assays (at pH > 6.5)^[1].
BMS-767778 exhibits low plasma protein binding across species: 18% (human), 14% (mouse), 28% (rat), 27% (dog), and 16% (monkey) ^[1].
BMS-767778 demonstrates a low metabolic turnover in both liver microsomes and hepatocytes, and correspondingly, a low hepatic clearance is predicted in humans^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BMS-767778 (compound 2s) (0.15-5.0 mg/kg, o.p., once) significantly reduces blood glucose levels in high fat fed (HFD) ob/ob mice^[1].
BMS-767778 (500 mg/kg, o.p., once) results no clinical chemistry or hemotology changes in rats^[1].
BMS-767778 (300 mg/kg, o.p., 14 days) results no clinical chemistry or hemotology changes in rats^[1].
BMS-767778 (25 mg/kg, o.p., 5 days) produces no significant changes in dogs^[1].
BMS-767778 (50 mg/kg, o.p., 5 days) results a softening of stools in dog^[1].
BMS-767778 (50 mg/kg) not demonstrate any potential for undesirable cardiovascular activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

407.29

C₁₉H₂₀Cl₂N₄O₂

915729-95-2

O=C(N(C)C)CN1CC2=NC(C)=C(CN)[C@]([C@]3=CC=C(Cl)C=C3Cl)=C2C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pratik Devasthale, et al. Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem . 2013 Sep 26;56(18):7343-57.  [Content Brief]

  [2]. Devasthale P, et al, Hamann LG. Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem. 2013 Sep 26;56(18):7343-57.  [Content Brief]